Key reasons to consider an investment in ProMIS Neurosciences
- Massive market opportunity and unmet medical need in Alzheimer’s disease. No therapies available today to stop the progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS product candidates are uniquely designed to selectively block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.
- Management team. Experienced, complementary management team with outstanding scientific and business advisory boards.
- Significant risk mitigation/reduction of ProMIS proposed product candidates. Big pharma has spent $BB on failed, or partially successful clinical trials in AD. Results of these trials clearly indicate the ideal target product profile to develop, i.e., to succeed, products must target the toxic prion forms of Amyloid beta, and not target the other forms of Amyloid beta. ProMIS products are designed to selectively target these toxic strains of Amyloid beta, supporting a highly differentiated, best in class product profile.
- ProMIS proprietary discovery engine supports development of a broad product portfolio in neurodegenerative diseases. Use of the ProMIS discovery platform allows to identify novel therapeutic targets on various toxic, misfolded proteins responsible for multiple neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, and other dementias such as Lewy Body dementia, frontotemporal dementia, and chronic head trauma